Project Details
Description
PUBLIC ABSTRACT
Monitoring of breast cancer therapy has been clinically problematic as current methods correlate poorly with patient assessment and outcome. Currently, an individual must serve as her own longitudinal control, and therefore, response is only assessed after several therapy cycles, incurring toxicity, costs, and delays. New methods to monitor disease progression and response to therapy are needed to improve patient care. We have developed a hybrid vector enabling targeted molecular-genetic imaging to assess and possibly predict therapeutic response. We propose to study these targeted imaging approaches in the setting of breast cancer toward development of new diagnostic and therapeutic tools. If successful, targeted molecular imaging and prediction of drug response will be a major advance in the management of breast cancer and may improve the sensitivity and specificity of standard measurements. We have created a new class of hybrid virus and demonstrated its ability to find, highlight, and deliver genes to breast cancer in mice. This advance, reported in the prestigious scientific journal Cell, is potentially an important step in making human cancer both more visible and accessible to treatment; it may also allow one to predict and monitor if and how specific anti-cancer agents are actually working. In tumor-bearing mice, we show that this hybrid virus can target tumors systemically to deliver an imaging or therapeutic gene. The signal is specific only to tumors, so one can also monitor anti-tumor activity. We created and characterized the hybrid viruses by combining genetic elements and biological attributes of an animal virus (adeno-associated virus, or AAV) with those of a bacterial virus (phage). Unlike animal viruses that infect mammalian cells, bacterial viruses have evolved to infect only bacterial hosts. The paper shows how particles of the hybrid virus, called AAV phage or AAVP, can serve as a vehicle for targeted delivery of genes to experimental tumors in mice and to the tumor blood vessel supply, providing a strategy for finding tumors and genetically marking them for imaging on a clinic-ready body scanner. The AAVP hybrid combines the ability of the bacterial virus to target specific tissues with the capability of the mammalian virus to actually deliver genes to cells. In addition to the obvious biological interest, when the vector is refined for patient use, it will help us diagnose, monitor, and treat breast cancer more accurately. These findings are the latest in a series of studies by our laboratory that are built around our discovery that the human vasculature system contains unique molecular addresses. Organs and specialized tissues also have specific "zip codes" on their blood vessels, as do tumor blood vessels. Discussions with the Food and Drug Association are in progress related to the first clinical trial based on a tumor vasculature zip code discovered using combinatorial screenings in patients. In this Impact proposal, we propose to design, construct, evaluate, and validate breast cancer targeted AAVP systems. This vector system has recently been studied in pet tumor-bearing dogs, with most promising results, adding credibility to the possible success of the system in clinical trials. Tumor-bearing dogs, unlike breast cancer models established in mice, are spontaneous and develop over long periods of time, and model the human disease more closely. We already know, by using positron emission tomography, that reporter and therapeutic genes can be expressed throughout tumors in animal models of breast cancer using AAVP. This is an example of the so-called "theragnostic" approach, a combination of the words therapeutic and diagnostic. We now plan to evaluate the safety and efficacy of other versions of hybrid vectors in breast cancer, carry out toxicology studies, and plan for a clinical trial. Ultimately, there is the goal of adapting and optimizing the AAVP-based targeting prototype for use in patients. If successful, we will generate and validate novel AAVP constructs for molecular imaging of breast cancer in relevant preclinical human breast cancer xenograft models. Targeted molecular imaging and prediction of drug response would be a major advance in the management of breast cancer and may improve the sensitivity and specificity of standard measurements. Given that many of our peptides and phage vectors target angiogenic vasculature as well as breast cancer cells, these studies will integrate and enhance the effectiveness of ligand-directed transcriptional targeting and imaging technologies. Clinical trials based on this novel imaging platform technology are expected to begin in the near future, as the work proposed here is completed.
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/08 → 12/31/08 |